2/7/2026

Janusmed kön och genus

Janusmed kön och genus – RINVOQ

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Upadacitinib

Upadacitinib

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. RINVOQ (upadacitinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-11-17, cited 2026-01-19]

  2. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford). 2010;49(8):1563-9.

  3. Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17(1):118.

  4. Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024.

  5. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39(1):57-68.

  6. Moreel L, Betrains A, Molenberghs G, Vanderschueren S, Blockmans D. Epidemiology and predictors of relapse in giant cell arteritis: A systematic review and meta-analysis. Joint Bone Spine. 2023;90(1):105494.

  7. Sharma A, Mohammad AJ, Turesson C. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. Semin Arthritis Rheum. 2020;50(5):1040-1048.

  8. Mohammad AJ, Nilsson JÅ, Jacobsson LT, Merkel PA, Turesson C. Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. Ann Rheum Dis. 2015;74(6):993-7.

  9. Johansson EK, Bergström A, Kull I, Melén E, Jonsson M, Lundin S et al. Prevalence and characteristics of atopic dermatitis among young adult females and males-report from the Swedish population-based study BAMSE. J Eur Acad Dermatol Venereol. 2022;36(5):698-704.

  10. Nader A, Stodtmann S, Friedel A, Mohamed MF, Othman AA. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials. J Clin Pharmacol. 2020;60(4):528-539.

  11. Klünder B, Mohamed MF, Othman AA. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials. Clin Pharmacokinet. 2018;57(8):977-988.

  12. Klünder B, Mittapalli RK, Mohamed MF, Friedel A, Noertersheuser P, Othman AA. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. Clin Pharmacokinet. 2019;58(8):1045-1058.

  13. Martinez-Molina C, Feliu A, Park HS, Juanes A, Diaz-Torne C, Vidal S et al. Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?. J Clin Med. 2024;13(8):.

  14. Martinez-Molina C, Vidal S, Diaz-Torne C, Park HS, Corominas H. Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment. Front Med (Lausanne). 2025;12:1512501.

  15. Luchetti Gentiloni MM, Paci V, Carletto A, Zabotti A, Ramonda R, Chimenti MS et al. Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study. Arthritis Res Ther. 2023;25(1):196.

  16. Thyssen JP, Thaçi D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W et al. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023;37(9):1871-1880.

  17. Food and Drug Administration (FDA). Clinical Review - RINVOQ (upadacitinib). Drugs@ [www]. [updated 2019-09-12, cited 2026-01-27].

  18. Baldi C, Gentileschi S, Li Gobbi F, Cazzato M, Delle Sedie A, Gaggiano C et al. Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study. Clin Exp Med. 2025;25(1):50.

  19. Leon L, Bermejo PP, Laredo L, Peña Pedrosa JA, Benítez Gimenez MT, Freites D et al. JAK1-selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis. Ther Adv Musculoskelet Dis. 2025;17:1759720X251393130.

  20. Martinez-Molina C, Gich I, Diaz-Torné C, Park HS, Feliu A, Vidal S et al. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Sci Rep. 2024;14(1):172.

  21. Qian J, Xue X, Shannon J. Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration. J Manag Care Spec Pharm. 2022;28(9):1046-1052.

  22. Yuan J, Lu H, Zuo X, Yin L, Pu Y, Zhang J. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database. Pharmacoepidemiol Drug Saf. 2024;33(10):e70030.

  23. Altınöz Güney C, Koç HA. Investigation of infection risk associated with Janus kinase inhibitors: a pharmacovigilance analysis using the Food and Drug Administration's Adverse Event Reporting System database. Clin Exp Dermatol. 2026;51(2):226-235.

  24. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. RINVOQ (upadacitinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-11-17, cited 2026-01-19]
  2. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford). 2010;49(8):1563-9.
  3. Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17(1):118.
  4. Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024.
  5. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39(1):57-68.
  6. Moreel L, Betrains A, Molenberghs G, Vanderschueren S, Blockmans D. Epidemiology and predictors of relapse in giant cell arteritis: A systematic review and meta-analysis. Joint Bone Spine. 2023;90(1):105494.
  7. Sharma A, Mohammad AJ, Turesson C. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. Semin Arthritis Rheum. 2020;50(5):1040-1048.
  8. Mohammad AJ, Nilsson JÅ, Jacobsson LT, Merkel PA, Turesson C. Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. Ann Rheum Dis. 2015;74(6):993-7.
  9. Johansson EK, Bergström A, Kull I, Melén E, Jonsson M, Lundin S et al. Prevalence and characteristics of atopic dermatitis among young adult females and males-report from the Swedish population-based study BAMSE. J Eur Acad Dermatol Venereol. 2022;36(5):698-704.
  10. Nader A, Stodtmann S, Friedel A, Mohamed MF, Othman AA. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials. J Clin Pharmacol. 2020;60(4):528-539.
  11. Klünder B, Mohamed MF, Othman AA. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials. Clin Pharmacokinet. 2018;57(8):977-988.
  12. Klünder B, Mittapalli RK, Mohamed MF, Friedel A, Noertersheuser P, Othman AA. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. Clin Pharmacokinet. 2019;58(8):1045-1058.
  13. Martinez-Molina C, Feliu A, Park HS, Juanes A, Diaz-Torne C, Vidal S et al. Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?. J Clin Med. 2024;13(8):.
  14. Martinez-Molina C, Vidal S, Diaz-Torne C, Park HS, Corominas H. Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment. Front Med (Lausanne). 2025;12:1512501.
  15. Luchetti Gentiloni MM, Paci V, Carletto A, Zabotti A, Ramonda R, Chimenti MS et al. Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study. Arthritis Res Ther. 2023;25(1):196.
  16. Thyssen JP, Thaçi D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W et al. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023;37(9):1871-1880.
  17. Food and Drug Administration (FDA). Clinical Review - RINVOQ (upadacitinib). Drugs@ [www]. [updated 2019-09-12, cited 2026-01-27].
  18. Baldi C, Gentileschi S, Li Gobbi F, Cazzato M, Delle Sedie A, Gaggiano C et al. Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study. Clin Exp Med. 2025;25(1):50.
  19. Leon L, Bermejo PP, Laredo L, Peña Pedrosa JA, Benítez Gimenez MT, Freites D et al. JAK1-selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis. Ther Adv Musculoskelet Dis. 2025;17:1759720X251393130.
  20. Martinez-Molina C, Gich I, Diaz-Torné C, Park HS, Feliu A, Vidal S et al. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Sci Rep. 2024;14(1):172.
  21. Qian J, Xue X, Shannon J. Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration. J Manag Care Spec Pharm. 2022;28(9):1046-1052.
  22. Yuan J, Lu H, Zuo X, Yin L, Pu Y, Zhang J. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database. Pharmacoepidemiol Drug Saf. 2024;33(10):e70030.
  23. Altınöz Güney C, Koç HA. Investigation of infection risk associated with Janus kinase inhibitors: a pharmacovigilance analysis using the Food and Drug Administration's Adverse Event Reporting System database. Clin Exp Dermatol. 2026;51(2):226-235.
  24. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]